Novartis to Build First U.S. Plant for Cell-Based Flu Vaccine

The U.S. Department of Health and Human Services said it has given a $487 million contract to Novartis Vaccines and Diagnostics, Inc., to build the first U.S. facility to manufacture cell-based vaccine for seasonal and pandemic flu. The plant is to be built in Holly Springs, N.C., with HHS paying 40 percent of its cost and Novartis paying 60 percent, the federal agency said.

Cell-based influenza vaccine can be made faster and in larger quantities than traditional vaccine, and the new plant is expected to increase the U.S. capacity to make pandemic flu vaccine by at least 25 percent, according to HHS. It will help with response to surge capacity needs becaose cells can be frozen and stored or developed quickly in response to an epidemic. "Cell-based vaccine production also dramatically reduces the possibility for contamination and promises to be more reliable, flexible, and expandable than egg-based methods," said HHS. "Currently, influenza vaccines licensed by the U.S. Food and Drug Administration (FDA) are made in specialized chicken eggs using a process that has changed little in over 50 years. In place of eggs, cell-based vaccine production uses laboratory-grown cells that are capable of hosting a growing virus. The virus is injected into the cells where it multiplies. The cells' outer walls are removed, harvested, purified, and inactivated. Using this technology, a vaccine can be produced in a matter of weeks."

"Today we are taking an important step in our ongoing commitment to pandemic preparedness," said Dr. Robin Robinson, director of the HHS Biomedical Advanced Research and Development Authority, which will oversee the contract. "In a pandemic, we would need vaccine ready within six months. That's why the National Strategy for Pandemic Influenza set domestic surge capacity as a goal in preparing the nation for a pandemic. That goal could not be accomplished using the traditional egg-based method of producing flu vaccine."

The contract calls for Novartis to provide two new flu vaccines for seasonal flu or pre-pandemic use, and the contract will fund clinical bridging studies to compare existing Novartis vaccines to new ones, including those developed in the Holly Springs plant -- thought to be a faster way to demonstrate the new ones are safe and effective.

Download Center

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • Online Safety Training Buyer's Guide

    Use this handy buyer's guide to learn the basics of selecting online safety training and how to use it at your workplace.

  • COVID Return-to-Work Checklist, Fall 2021

    Use this checklist as an aid to help your organization return to work during the COVID-19 pandemic in a safe and healthy manner.

  • SDS Buyer's Guide

    Learn to make informed decisions while searching for SDS Management Software.

  • Risk Matrix Guide

    Risk matrices come in many different shapes and sizes. Understanding the components of a risk matrix will allow you and your organization to manage risk effectively.

  • Industry Safe

Featured Whitepapers

OH&S Digital Edition

  • OHS Magazine Digital Edition - October 2021

    October 2021

    Featuring:

    • TRAINING
      On Route To Safe Material Handling
    • SAFETY CULTURE
      Normalization of Deviations in Performance
    • IH:INDOOR AIR QUALITY
      Arresting Fugitive Dusts
    • PPE:FOOT PROTECTION
      Safety Shoes Make the Outfit for Well-Protected Workers
    View This Issue